Targeting MET alongside VEGF inhibition with the small-molecule kinase inhibitor, cabozantinib, can reduce tumor aggressiveness in pre-clinical pancreatic and neuroblastoma cancers [170,171]. This evidence concerns the gene MET and neoplasm.